Overview of the main hormones associated with alteration of bone and mineral metabolism in patients with chronic kidney disease

Sponsored by: Diasorin

Speaker

Jean-Claude Souberbielle (JCS)

Ex head of Laboratoire d'explorations fonctionnelles hôpital Necker-Enfants malades
BIOGRAPHY

Event Date & Time

DATE: December 6, 2018

TIME: 6:00am PST, 9:00am EST, 3:00pm CET

Abstract

Alterations in the bone and mineral metabolism is of great concern in patients with chronic kidney disease (CKD). As the glomerular filtration rate (GFR) decreases, phosphatemia tends to increase while the renal secretion of the active vitamin D metabolite decreases with, consequently, increases in both serum PTH and FGF23 levels. This the pathophysiological basis of the so-called CKD-bone and mineral disorders (MBD). Experts in Nephrology have published international guidelines, called the KDIGO/CKD-MBD, to help the colleagues to deal with these disorders. In this webinar, the KDIGO recommendations concerning the measurement of the serum concentration of PTH, vitamin D metabolites and FGF23 will be discussed.

Learning Objective:

Understand the bone metabolic disorder in CKD patients
Which is the mechanism that regulate the calcium and phosphorus absorption in patient with altered hormone activities
Know the utility of a few fundamental markers to decide the CKD patient management

Overview of the main hormones associated with alteration of bone and mineral metabolism in patients with chronic kidney disease

Overview of the main hormones associated with alteration of bone and mineral metabolism in patients with chronic kidney disease

Jean-Claude Souberbielle (JCS)

Overview of the main hormones associated with alteration of bone and mineral metabolism in patients with chronic kidney disease